List view / Grid view
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
25 April 2017 | By Niamh Marriott, Junior Editor
The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis...
4 August 2016 | By National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....
18 July 2016 | By Victoria White, Digital Content Producer
At an estimated $4billion a year, the reference product, Humira, is among the European Union's largest single drug expenditures...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
31 May 2016 | By Victoria White, Digital Content Producer
The EC has granted marketing authorisation in the European Union (EU) for Flixabi, an infliximab biosimilar referencing Remicade...
16 February 2016 | By Victoria White
A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
23 October 2015 | By Victoria White
Cosentyx Phase III studies have consistently demonstrated significant improvements in the signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
11 June 2015 | By Victoria White
Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR...
11 June 2014 | By AbbVie
AbbVie announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases...
